ASCO 2024 – Enhertu nears its “ultralow” dream
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
ASCO 2024 – Krazati looks more similar than different to Lumakras
Meanwhile, Lilly gets in on the next-gen KRAS action.
ASCO 2024 – Summit peaks on ivonescimab surprise
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
ASCO 2024 – Scemblix could set new standard in front-line leukaemia
But will the FDA accept the surrogate endpoint used in ASC4First?
ASCO 2024 – J&J flies towards a more convenient Rybrevant
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
ASCO 2024 preview – conjugates in focus
This weekend’s oncology conference will feature at least 30 different ADC projects.
